04/29/2026
The future of testosterone therapy. Meet Andrenyx™.
Medivant Healthcare is proud to announce the launch of Andrenyx™ (compounded testosterone cypionate) a single-dose prefilled syringe engineered for precision, sterility, and real-world clinical usability.
Manufactured at our fully automated, FDA-registered and inspected 503B outsourcing facility in Phoenix, AZ — built to pharmaceutical-grade CGMP standards.
What sets Andrenyx™ (compounded testosterone) apart:
→ Single-dose precision — pre-measured, pre-filled, ready to administer. No drawing errors. No measurement guesswork.
→ Subcutaneous-ready — formulated in MCT oil for lower viscosity, making SubQ administration practical, not just possible.
→ 12-month beyond-use date — significantly longer stability than patient-managed multi-dose vials.
→ Tamper-evident, sterile, single-use — every dose arrives sealed and ready, with full product integrity.
→ Six strengths — 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, and 200 mg, supplied in packs of 4 — covering the full clinical prescribing range without compromise.
Available for shipment to DEA-licensed facilities in states where Medivant Healthcare holds an active pharmacy license.
Andrenyx™ is available for shipping in June. Prescribers and facilities interested in early access, reach out today.
🌐 www.andrenyx.com
📧 [email protected]
📞 1-888-201-0688
Andrenyx™ (compounded testosterone cypionate) is a compounded drug product. It is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. Compounded drugs are permitted to be prescribed under federal law but are not equivalent to FDA-approved drugs. This product is available exclusively for purchase by DEA-licensed facilities.